**Core Concept**
The hepatitis B vaccine is a recombinant vaccine that protects against hepatitis B virus (HBV) infection by inducing antibodies against the surface antigen (HBsAg) of the virus. The vaccine stimulates the production of immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies against HBsAg.

**Why the Correct Answer is Right**
After completing the hepatitis B vaccine series, the student can be expected to have developed immunity against HBV, characterized by the presence of protective levels of antibodies against HBsAg. The antibodies will neutralize the virus, preventing it from infecting liver cells and causing disease. The presence of these antibodies indicates successful vaccination and provides long-term protection against HBV infection.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not relevant to the expected outcome of hepatitis B vaccination.
* **Option B:** This option is incorrect because it does not accurately reflect the expected outcome of hepatitis B vaccination.
* **Option C:** This option is incorrect because it does not accurately reflect the expected outcome of hepatitis B vaccination.
* **Option D:** This option is incorrect because it does not accurately reflect the expected outcome of hepatitis B vaccination.

**Clinical Pearl / High-Yield Fact**
It is essential to note that vaccination against HBV does not provide immediate protection. It takes 2-4 weeks for the body to develop an immune response after the first dose, and 2-3 months for the body to achieve maximum protection after completing the full vaccine series.

**Correct Answer: A. Antibodies against HBsAg.**